Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis
- PMID: 8834911
- PMCID: PMC163147
- DOI: 10.1128/AAC.40.2.503
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis
Abstract
We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.
Similar articles
-
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.Infection. 1998 Nov-Dec;26(6):379-84. doi: 10.1007/BF02770840. Infection. 1998. PMID: 9861564
-
Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.J Hepatol. 1999 Aug;31(2):277-83. doi: 10.1016/s0168-8278(99)80225-6. J Hepatol. 1999. PMID: 10453941
-
Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis.J Antimicrob Chemother. 1999 Jul;44(1):117-20. doi: 10.1093/jac/44.1.117. J Antimicrob Chemother. 1999. PMID: 10459819
-
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.Hepatology. 1999 Apr;29(4):1064-9. doi: 10.1002/hep.510290406. Hepatology. 1999. PMID: 10094947
-
Norfloxacin.2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2020 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643189 Free Books & Documents. Review.
Cited by
-
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):111-8. doi: 10.1007/s10096-005-1278-x. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15714332
-
Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.J Infect Dis. 2009 Aug 1;200(3):390-8. doi: 10.1086/600122. J Infect Dis. 2009. PMID: 19563257 Free PMC article. Clinical Trial.
-
Test characteristics of perirectal and rectal swab compared to stool sample for detection of fluoroquinolone-resistant Escherichia coli in the gastrointestinal tract.Antimicrob Agents Chemother. 2005 Feb;49(2):798-800. doi: 10.1128/AAC.49.2.798-800.2005. Antimicrob Agents Chemother. 2005. PMID: 15673772 Free PMC article. Clinical Trial.
-
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis.Infection. 1998 Nov-Dec;26(6):379-84. doi: 10.1007/BF02770840. Infection. 1998. PMID: 9861564
-
Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.Haematologica. 2016 Oct;101(10):1208-1215. doi: 10.3324/haematol.2016.147934. Epub 2016 Jul 28. Haematologica. 2016. PMID: 27470601 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical